Efficacy and safety of DBPR108 (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized, double‐blind, placebo‐controlled, superiority, phase III clinical trial

AIM: To evaluate the efficacy and safety of DBPR108 (prusogliptin), a novel dipeptidyl peptidase‐4 (DPP‐4) inhibitor, as an add‐on therapy in patients with type 2 diabetes (T2D) that is inadequately controlled with metformin. MATERIALS AND METHODS: In this 24‐week, multi‐centre, randomized, double‐b...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianping, Ling, Hongwei, Geng, Jianlin, Huang, Yanli, Xie, Ying, Zheng, Huiping, Niu, Huikun, Zhang, Tianhao, Yuan, Jing, Xiao, Xinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796963/
https://www.ncbi.nlm.nih.gov/pubmed/35791646
http://dx.doi.org/10.1111/dom.14810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796963/
https://www.ncbi.nlm.nih.gov/pubmed/35791646
http://dx.doi.org/10.1111/dom.14810

Ejemplares similares